The Role of Beta2-Microglobulin in Central Nervous System Disease

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Central nervous system (CNS) disorders represent the leading cause of disability and the second leading cause of death worldwide, and impose a substantial economic burden on society. In recent years, emerging evidence has found that beta2 -microglobulin (B2M), a subunit of major histocompatibility complex class I (MHC-I) molecules, plays a crucial role in the development and progression in certain CNS diseases. On the one hand, intracellular B2M was abnormally upregulated in brain tumors and regulated tumor microenvironments and progression. On the other hand, soluble B2M was also elevated and involved in pathological stages in CNS diseases. Targeted B2M therapy has shown promising outcomes in specific CNS diseases. In this review, we provide a comprehensive summary and discussion of recent advances in understanding the pathological processes involving B2M in CNS diseases (e.g., Alzheimer's disease, aging, stroke, HIV-related dementia, glioma, and primary central nervous system lymphoma).

Supplementary Information

The online version contains supplementary material available at 10.1007/s10571-024-01481-6.

Related collections

Most cited references 119

Record: found
Abstract: found
Article: not found

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Reisa Sperling, Paul S Aisen, Laurel A. Beckett … (2011)

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious. Copyright © 2011. Published by Elsevier Inc.

0 comments Cited 1140 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Karen Courville, Sergei Ermakov, Maheswar Satpathy … (2015)

The Lancet, 385(9963), 117-171

1 comments Cited 979 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Ageing as a risk factor for neurodegenerative disease

Yujun Hou, Xiuli Dan, Mansi Babbar … (2019)

Ageing is the primary risk factor for most neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD). One in ten individuals aged ≥65 years has AD and its prevalence continues to increase with increasing age. Few or no effective treatments are available for ageing-related neurodegenerative diseases, which tend to progress in an irreversible manner and are associated with large socioeconomic and personal costs. This Review discusses the pathogenesis of AD, PD and other neurodegenerative diseases, and describes their associations with the nine biological hallmarks of ageing: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem cell exhaustion and altered intercellular communication. The central biological mechanisms of ageing and their potential as targets of novel therapies for neurodegenerative diseases are also discussed, with potential therapies including NAD+ precursors, mitophagy inducers and inhibitors of cellular senescence.

0 comments Cited 921 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Ze-Fen Wang:

ORCID: http://orcid.org/0000-0002-0194-2521

wangzf@whu.edu.cn

Zhi-Qiang Li:

ORCID: http://orcid.org/0000-0002-4148-780X

lizhiqiang@whu.edu.cn

Journal

Journal ID (nlm-ta): Cell Mol Neurobiol

Journal ID (iso-abbrev): Cell Mol Neurobiol

Title: Cellular and Molecular Neurobiology

Publisher: Springer US (New York )

ISSN (Print): 0272-4340

ISSN (Electronic): 1573-6830

Publication date (Electronic): 14 May 2024

Publication date PMC-release: 14 May 2024

Publication date (Print): 2024

Volume: 44

Issue: 1

Electronic Location Identifier: 46

Affiliations

[1 ]Brain Glioma Center & Department of Neurosurgery, Zhongnan Hospital of Wuhan University, ( https://ror.org/01v5mqw79) Wuhan, Hubei China

[2 ]Department of Physiology, Wuhan University School of Basic Medical Sciences, ( https://ror.org/033vjfk17) Wuhan, Hubei China

Author information

Zhen-Yuan Liu http://orcid.org/0000-0002-6534-3229

Feng Tang http://orcid.org/0000-0003-3185-5717

Jin-Zhou Yang http://orcid.org/0000-0002-8046-5953

Xi Chen http://orcid.org/0000-0002-7213-7271

Ze-Fen Wang http://orcid.org/0000-0002-0194-2521

Zhi-Qiang Li http://orcid.org/0000-0002-4148-780X

Article

Publisher ID: 1481

DOI: 10.1007/s10571-024-01481-6

PMC ID: 11093819

PubMed ID: 38743119

SO-VID: 64762e62-3eae-4a7e-88d9-dda2949570b1

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 6 January 2024

Date accepted : 10 May 2024

Funding

Funded by: the National Natural Science Foundation of China

Award ID: No.82273328

Award Recipient : Zhi-Qiang Li

Custom metadata

ScienceOpen disciplines: Neurosciences

Keywords: beta2-microglobulin,central nervous system diseases,biomarker

Data availability:

ScienceOpen disciplines: Neurosciences

Keywords: beta2-microglobulin, central nervous system diseases, biomarker

The Role of Beta2-Microglobulin in Central Nervous System Disease

Read this article at

Abstract

Supplementary Information

Related collections

The Dynamic Brain

Most cited references 119

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Ageing as a risk factor for neurodegenerative disease

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 405

Most referenced authors 4,787